ABSTRACT
Financial compensation to participants in clinical trials for the immediate and long-term medical treatment of injuries sustained while participating in the trials, and payment to their next of kin when such injuries result in death, is a relatively neglected subject, particularly in developing countries.
ABSTRACT
Background: The GeneXpert® MTB/RIF (hereinafter Xpert) test has demonstrated sensitive detection of tuberculosis (TB) and Rifampicin resistance directly from untreated sputum in less than two hours. India is currently drafting the third phase of its Revised National Tuberculosis Control Programme (RNTCP). This process provides the country’s health authorities with an ideal opportunity to revolutionise TB management in the country. The RNTCP is currently conducting a multi–site demonstration study to gather operational evidence to scale up the Xperttest under Indian programme conditions.